New Product - Cabometyx
Cabometyx (cabozantinib) inhibits multiple receptor tyrosine kinases implicated in tumour growth and angiogenesis, and metastatic progression of cancer. Cabozantinib is an inhibitor of MET (hepatocyte growth factor receptor protein) and VEGF (vascular endothelial growth factor) receptors. In addition, cabozantinib inhibits other tyrosine kinases including AXL, RET, ROS1, TYRO3, MER, KIT, TRKB, FLT3 and TIE-2. Cabometyx is indicated for the treatment of advanced renal cell carcinoma in adults following prior treatment with VEGF targeted therapy. Cabometyx 20 mg, 40 mg and 60 mg tablets are available in packs of 30.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629